Viking Therapeutics is making waves in the weight loss drug market with promising candidates in phase 3 and phase 2 studies, boosting stock prices by over 120%. Despite a recent decline, shares have gained 16% in the past three months. With potential catalysts ahead, including poster presentations at medical conferences, Viking’s candidate showed up to 13.1% weight loss in phase 2. Analysts predict the weight loss market could reach $100 billion by 2030. Viking’s candidate could offer a significant opportunity, though comparisons to existing drugs are challenging. Consider investing in this biotech as momentum picks up.

Read more at Yahoo Finance: Should You Buy Viking Therapeutics Before Nov. 5?